<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Merck & Co Inc (NYSE: MRK) has announced overall survival (OS) results from Phase 3 KEYNOTE-355 trial evaluating Keytruda (pembrolizumab) in combination with chemotherapy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC). Final analysis show first-line treatment with Keytruda/Chemo combo demonstrated a statistically significant and clinically meaningful improvement in OS compared with chemotherapy alone in patients with mTNBC whose tumors expressed PD-L1.
...read full article on Benzinga
